Management of Adverse Events Following Treatment With Anti‐Programmed Death‐1 Agents
Weber, Jeffrey S., Postow, Michael, Lao, Christopher D., Schadendorf, Dirk
Published in The oncologist (Dayton, Ohio) (01.10.2016)
Published in The oncologist (Dayton, Ohio) (01.10.2016)
Get full text
Journal Article
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, Hussein A, Schadendorf, Dirk, Lipson, Evan J, Ascierto, Paolo A, Matamala, Luis, Castillo Gutiérrez, Erika, Rutkowski, Piotr, Gogas, Helen J, Lao, Christopher D, De Menezes, Juliana Janoski, Dalle, Stéphane, Arance, Ana, Grob, Jean-Jacques, Srivastava, Shivani, Abaskharoun, Mena, Hamilton, Melissa, Keidel, Sarah, Simonsen, Katy L, Sobiesk, Anne Marie, Li, Bin, Hodi, F. Stephen, Long, Georgina V
Published in The New England journal of medicine (06.01.2022)
Published in The New England journal of medicine (06.01.2022)
Get full text
Journal Article
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Hodi, Frank Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Cowey, Charles Lance, Lao, Christopher D, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Hill, Andrew, Hogg, David, Marquez-Rodas, Ivan, Jiang, Joel, Rizzo, Jasmine, Larkin, James, Wolchok, Jedd D
Published in The lancet oncology (01.11.2018)
Published in The lancet oncology (01.11.2018)
Get full text
Journal Article
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Lin, Heng, Wei, Shuang, Hurt, Elaine M, Green, Michael D, Zhao, Lili, Vatan, Linda, Szeliga, Wojciech, Herbst, Ronald, Harms, Paul W, Fecher, Leslie A, Vats, Pankaj, Chinnaiyan, Arul M, Lao, Christopher D, Lawrence, Theodore S, Wicha, Max, Hamanishi, Junzo, Mandai, Masaki, Kryczek, Ilona, Zou, Weiping
Published in The Journal of clinical investigation (01.02.2018)
Published in The Journal of clinical investigation (01.02.2018)
Get full text
Journal Article
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, Jeffrey S, Dr, D'Angelo, Sandra P, MD, Minor, David, MD, Hodi, F Stephen, MD, Gutzmer, Ralf, MD, Neyns, Bart, MD, Hoeller, Christoph, MD, Khushalani, Nikhil I, MD, Miller, Wilson H, MD, Lao, Christopher D, MD, Linette, Gerald P, MD, Thomas, Luc, MD, Lorigan, Paul, FRCP, Grossmann, Kenneth F, MD, Hassel, Jessica C, MD, Maio, Michele, MD, Sznol, Mario, MD, Ascierto, Paolo A, MD, Mohr, Peter, MD, Chmielowski, Bartosz, MD, Bryce, Alan, MD, Svane, Inge M, MD, Grob, Jean-Jacques, MD, Krackhardt, Angela M, MD, Horak, Christine, PhD, Lambert, Alexandre, PhD, Yang, Arvin S, MD, Larkin, James, FRCP
Published in The lancet oncology (01.04.2015)
Published in The lancet oncology (01.04.2015)
Get full text
Journal Article
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, Hussein A, Forsyth, Peter A, Algazi, Alain, Hamid, Omid, Hodi, F. Stephen, Moschos, Stergios J, Khushalani, Nikhil I, Lewis, Karl, Lao, Christopher D, Postow, Michael A, Atkins, Michael B, Ernstoff, Marc S, Reardon, David A, Puzanov, Igor, Kudchadkar, Ragini R, Thomas, Reena P, Tarhini, Ahmad, Pavlick, Anna C, Jiang, Joel, Avila, Alexandre, Demelo, Sheena, Margolin, Kim
Published in The New England journal of medicine (23.08.2018)
Published in The New England journal of medicine (23.08.2018)
Get full text
Journal Article
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
Larkin, James, Minor, David, D'Angelo, Sandra, Neyns, Bart, Smylie, Michael, Miller, Jr, Wilson H, Gutzmer, Ralf, Linette, Gerald, Chmielowski, Bartosz, Lao, Christopher D, Lorigan, Paul, Grossmann, Kenneth, Hassel, Jessica C, Sznol, Mario, Daud, Adil, Sosman, Jeffrey, Khushalani, Nikhil, Schadendorf, Dirk, Hoeller, Christoph, Walker, Dana, Kong, George, Horak, Christine, Weber, Jeffrey
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Schadendorf, Dirk, Wolchok, Jedd D, Hodi, F Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C Lance, Lao, Christopher D, Chesney, Jason, Robert, Caroline, Grossmann, Kenneth, McDermott, David, Walker, Dana, Bhore, Rafia, Larkin, James, Postow, Michael A
Published in Journal of clinical oncology (01.12.2017)
Published in Journal of clinical oncology (01.12.2017)
Get full text
Journal Article
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Butler, Marcus O, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John B A G, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bas, Tuba, Ritchings, Corey, Larkin, James, Hodi, F Stephen
Published in Journal of clinical oncology (10.01.2022)
Published in Journal of clinical oncology (10.01.2022)
Get full text
Journal Article
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Sekulic, Aleksandar, Migden, Michael R, Basset-Seguin, Nicole, Garbe, Claus, Gesierich, Anja, Lao, Christopher D, Miller, Chris, Mortier, Laurent, Murrell, Dedee F, Hamid, Omid, Quevedo, Jorge F, Hou, Jeannie, McKenna, Edward, Dimier, Natalie, Williams, Sarah, Schadendorf, Dirk, Hauschild, Axel
Published in BMC cancer (16.05.2017)
Published in BMC cancer (16.05.2017)
Get full text
Journal Article
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C. Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier F, Smylie, Michael, Hogg, David, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bastholt, Lars, Rizzo, Jasmine I, Balogh, Agnes, Moshyk, Andriy, Hodi, F. Stephen, Wolchok, Jedd D
Published in The New England journal of medicine (17.10.2019)
Published in The New England journal of medicine (17.10.2019)
Get full text
Journal Article
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Tawbi, Hussein A, Forsyth, Peter A, Hodi, F Stephen, Algazi, Alain P, Hamid, Omid, Lao, Christopher D, Moschos, Stergios J, Atkins, Michael B, Lewis, Karl, Postow, Michael A, Thomas, Reena P, Glaspy, John, Jang, Sekwon, Khushalani, Nikhil I, Pavlick, Anna C, Ernstoff, Marc S, Reardon, David A, Kudchadkar, Ragini, Tarhini, Ahmad, Chung, Caroline, Ritchings, Corey, Durani, Piyush, Askelson, Margarita, Puzanov, Igor, Margolin, Kim A
Published in The lancet oncology (01.12.2021)
Published in The lancet oncology (01.12.2021)
Get full text
Journal Article
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Yu, Jiali, Green, Michael D, Li, Shasha, Sun, Yilun, Journey, Sara N, Choi, Jae Eun, Rizvi, Syed Monem, Qin, Angel, Waninger, Jessica J, Lang, Xueting, Chopra, Zoey, El Naqa, Issam, Zhou, Jiajia, Bian, Yingjie, Jiang, Long, Tezel, Alangoya, Skvarce, Jeremy, Achar, Rohan K, Sitto, Merna, Rosen, Benjamin S, Su, Fengyun, Narayanan, Sathiya P, Cao, Xuhong, Wei, Shuang, Szeliga, Wojciech, Vatan, Linda, Mayo, Charles, Morgan, Meredith A, Schonewolf, Caitlin A, Cuneo, Kyle, Kryczek, Ilona, Ma, Vincent T, Lao, Christopher D, Lawrence, Theodore S, Ramnath, Nithya, Wen, Fei, Chinnaiyan, Arul M, Cieslik, Marcin, Alva, Ajjai, Zou, Weiping
Published in Nature medicine (01.01.2021)
Published in Nature medicine (01.01.2021)
Get full text
Journal Article
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
Larkin, James, Chmielowski, Bartosz, Lao, Christopher D., Hodi, F. Stephen, Sharfman, William, Weber, Jeffrey, Suijkerbuijk, Karijn P. M., Azevedo, Sergio, Li, Hewei, Reshef, Daniel, Avila, Alexandre, Reardon, David A.
Published in The oncologist (Dayton, Ohio) (01.06.2017)
Published in The oncologist (Dayton, Ohio) (01.06.2017)
Get full text
Journal Article
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Topalian, Suzanne L, Bhatia, Shailender, Amin, Asim, Kudchadkar, Ragini R, Sharfman, William H, Lebbé, Celeste, Delord, Jean-Pierre, Dunn, Lara A, Shinohara, Michi M, Kulikauskas, Rima, Chung, Christine H, Martens, Uwe M, Ferris, Robert L, Stein, Julie E, Engle, Elizabeth L, Devriese, Lot A, Lao, Christopher D, Gu, Junchen, Li, Bin, Chen, Tian, Barrows, Adam, Horvath, Andrea, Taube, Janis M, Nghiem, Paul
Published in Journal of clinical oncology (01.08.2020)
Published in Journal of clinical oncology (01.08.2020)
Get full text
Journal Article
IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation
Eto, Danelle, Lao, Christopher, DiToro, Daniel, Barnett, Burton, Escobar, Tania C, Kageyama, Robin, Yusuf, Isharat, Crotty, Shane
Published in PloS one (14.03.2011)
Published in PloS one (14.03.2011)
Get full text
Journal Article
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Lin, Heng, Wei, Shuang, Hurt, Elaine M, Green, Michael D, Zhao, Lili, Vatan, Linda, Szeliga, Wojciech, Herbst, Ronald, Harms, Paul W, Fecher, Leslie A, Vats, Pankaj, Chinnaiyan, Arul M, Lao, Christopher D, Lawrence, Theodore S, Wicha, Max, Hamanishi, Junzo, Mandai, Masaki, Kryczek, Ilona, Zou, Weiping
Published in The Journal of clinical investigation (02.04.2018)
Published in The Journal of clinical investigation (02.04.2018)
Get full text
Journal Article